entrinsic bioscience (EBS), a Norwood, Mass.-based company that aims to discover and patent precise combinations of amino acids with broad health and wellness applications as functional ingredients and APIs, secured $49m in non-dilutive growth financing.
Jefferies Funding acted as sole lender to EBS. The event follows Series A and B round, including multiple rounds of investment from Johnson & Johnson INNOVATION | JJDC. Aon Plc, using its proprietary intellectual property (IP) valuation platform to value EBS’ IP portfolio, arranged for an IP Collateral Insurance policy for Jefferies, collateralized by EBS’ IP portfolio. Insurers involved include Allianz, Aspen, and Markel.
entrinsic bioscience (EBS) combines a proprietary IP platform and discovery engine to deliver next generation functional ingredients and Active Pharmaceutical Ingredients (APIs) designed to address multiple consumer health conditions and serious disease states. Immediate applications include programs for GI, Airway Diseases and Skin.
FinSMEs
07/06/2021